Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a first-of-its-kind blood test. This test will predict the most likely origin of the cancer signal to help guide the next steps for diagnosis. Note that this will not detect all cancers, and false negatives and false positives may occur. This Galleri test should be used in tandem with provider-recommended screenings.
Here who is eligible for this free blood test:
Group 1 – Cancer Predisposition Syndrome (n=500):
- Age >22 for patients with TP53 germline pathogenic variants, age >35 for all other variants in cancer predisposing genes
- Germline genetic testing revealed pathogenic germline variants in cancer predisposing genes
- Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)
Exclusion Criteria
- Individuals diagnosed with invasive malignancy within 3 years of enrollment
- Have had a blood-based multi-cancer screening test within last year
- Individuals with evidence of symptomatic or active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is considered acceptable and will not preclude participation)
- Individuals in process of being evaluated for clinical suspicion of cancer
- Individuals who have undergone a cancer risk-reducing surgery for hereditary cancer risk (e.g., mastectomy).
- Individuals with known hematologic precursor disease (e.g. CHIP, MGUS, etc.)
